Summary
According to “The Wall Street Journal,” the average target price of 11 investment institutions covering Teva’s stock is $24.29, a 57.9% premium on the current share price.
Source: Globes
Exclusive AI-Powered News Insights (For Members only)
Disclaimer:This content is AI-generated from various trusted sources and is intended for informational purposes only. While we strive for accuracy, we encourage you to verify details independently. Use the contact button to share feedback on any inaccuracies—your input helps us improve!
